EGFR and non-small cell lung carcinoma: The current results complement previous findings that combined inhibition of EGFR signaling and the IAP-mediated anti-apoptotic pathway could fulfill a critical role in the treatment of human NSCLC cells, and ongoing further studies may provide better understanding for the working mechanism of this novel drug.